Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
SciSparc Ltd. - Ordinary Shares
(NQ:
SPRC
)
3.820
-0.110 (-2.80%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 17, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about SciSparc Ltd. - Ordinary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
SciSparc: AutoMax Enters the Direct Import Market with a $13 Million First Shipment of JAC Electric Vehicles
January 13, 2025
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results
January 07, 2025
From
SciSparc Ltd
Via
GlobeNewswire
Nasdaq Surges Over 200 Points; BioLineRx Shares Plummet
January 06, 2025
Via
Benzinga
S&P Jumps 1%; Regional Health Properties Shares Spike Higher
January 06, 2025
Via
Benzinga
Topics
Stocks
Why Is Psychedelic-SciSparc Stock Trading Higher On Monday?
January 06, 2025
SciSparc teams up with Clearmind Medicine on innovative therapies for binge behaviors and secures FDA approval for a Tourette Syndrome Phase 2b trial.
Via
Benzinga
US Stocks Open Higher; Dow Jumps Over 200 Points
January 06, 2025
Via
Benzinga
Topics
Stocks
SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment
January 06, 2025
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder
December 31, 2024
From
SciSparc Ltd
Via
GlobeNewswire
S&P 500 Edges Lower, SciSparc Shares Surge
December 26, 2024
Via
Benzinga
Topics
Stocks
Dow Gains 50 Points, SEALSQ Shares Plummet
December 26, 2024
Via
Benzinga
Topics
Stocks
Nasdaq Dips Over 100 Points, US Initial Jobless Claims Fall
December 26, 2024
Via
Benzinga
SciSparc Shares Skyrocket With AutoMax's First JAC Motors Shipment
December 26, 2024
SciSparc Ltd. shares are soaring after its merger-bound AutoMax Motors received its first shipment of JAC vehicles. The shipment positions AutoMax to begin marketing and sales activities for JAC Motors...
Via
Benzinga
Why Zoomcar Shares Are Trading Higher By Around 142%; Here Are 20 Stocks Moving Premarket
December 26, 2024
Via
Benzinga
SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation
December 26, 2024
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Provides Updates on Status of Spin-off of its Advanced Clinical Stage Pharmaceutical Portfolio to a Publicly Traded Company
December 16, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Pharma Company Gets FDA Green Light For Next Phase Trial For Tourette Syndrome
September 30, 2024
SciSparc secures FDA approval for Phase IIb clinical trial of SCI-110, targeting unmet needs in Tourette Syndrome, Global trial begins soon.
Via
Benzinga
SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment
September 30, 2024
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX
September 26, 2024
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment
September 23, 2024
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment
September 18, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Clearmind Medicine Files International Patent For Ibogaine Combination Therapy
September 17, 2024
Clearmind Medicine filed an international patent for a treatment that aims to enhance addiction treatment safety and efficacy.
Via
Benzinga
Topics
Intellectual Property
Why Intel Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
September 17, 2024
Via
Benzinga
SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy
September 16, 2024
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Advances $1.85 million Loan to AutoMax, Following AutoMax’s Direct Import Agreement with Major Chinese Vehicle Manufacturer
September 11, 2024
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
September 06, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
September 06, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination
August 29, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Why Affirm Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
August 29, 2024
Via
Benzinga
SciSparc Grants Global Rights for Pain Therapy to Biotech Company in Agreement Worth up to $6 Million
August 28, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Why MIRA Pharmaceuticals Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket
August 26, 2024
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today